SUBSCRIBE Blog with us: BLOGbiotech

Breaking News

• Email
• Print
• Share
• More News

May 8 2006, 7:01 AM EST

Kos Pharmaceuticals and SkyePharma to Host Teleconference on U.S. License Agreement to Market and Distribute Flutiform(TM)

News source: Business Wire

Kos Pharmaceuticals, Inc. (Nasdaq: KOSP), a fully integrated specialty pharmaceutical company, will host a conference call today at 8:30 a.m. ET with SkyePharma PLC (NASDAQ: SKYE; LSE: SKP) to discuss the exclusive license agreement for the marketing and distribution of Flutiform(TM) in the United States. Adrian Adams, President and Chief Executive Officer of Kos and Frank Condella, the Chief Executive Officer of SkyePharma will host the call.

The conference call will be available live via the Internet by accessing either company's website at www.kospharm.com and www.skyepharma.com. Please go to the respective websites at least fifteen minutes prior to the call to register, download and install any necessary audio software. Those who cannot access the webcast, can participate via telephone by calling 913-312-1295, confirmation code 6963745. A replay will also be available on both websites or by calling 719-457-0820 domestic or international, and entering 6963745 from 11:30 AM ET today until 11:59 PM ET on Friday, May 12, 2006.

If you would like to receive notices and news regarding Kos, please visit the Investor Relations section of the Company website and subscribe to email alerts.

Kos Pharmaceuticals, Inc. is a fully integrated specialty pharmaceutical company engaged in developing, commercializing, manufacturing and marketing proprietary prescription products for the treatment of chronic diseases with a particular focus on the cardiovascular, metabolic and respiratory disease areas. The Company's principal product development strategy is to reformulate existing pharmaceutical products with large market potential to improve safety, efficacy, and patient compliance. Kos' strategy also includes making measured investments in new chemical entity research through in-house and sponsored research, scientific in-licensing and general corporate development activities. The Company currently markets Niaspan(R) and Advicor(R) for the treatment of cholesterol disorders, Azmacort(R) for the treatment of asthma, Cardizem(R)LA for the treatment of hypertension and angina, and Teveten(R) and Teveten(R)HCT for the treatment of hypertension. Kos has a strong and growing research and development pipeline including proprietary drug delivery technologies in solid-dose, inhalation and aerosol metered-dose device administration to help fuel sustained, organic sales growth into the future.

Certain statements in this press release, including statements relating to the Company's strong and growing research and development pipeline and future sales growth are forward-looking and are subject to risks and uncertainties which may cause actual results to differ materially from those projected in a forward-looking statement. These risks and uncertainties include the Company's ability to successfully develop and commercialize new products under development, the Company's ability to enter into new business development and corporate opportunities, the progress of the company's research and development pipeline, the protection afforded by the Company's patents, the effect of conditions in the pharmaceutical industry and the economy in general, and the Company's ability to maintain compliance with FDA. A more detailed discussion of risks attendant to the forward-looking statements included in this press release are set forth in the "Forward-Looking information: Certain Cautionary Statements" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2005, filed with the Securities and Exchange Commission, and in other reports filed with the SEC.

• Email
• Print
• Share
• More News

CAREER CENTER

WEBINARS

PODCASTS

MOST POPULAR